PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

PacBio announced that its management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference. The event is scheduled for Tuesday, August 11, 2026, at 9:00 AM ET in Boston, Massachusetts. Investors can access a live webcast on the company's investor relations page, with a replay available for at least 30 days following the event.

PacBio announced it will host its second quarter 2026 financial results conference call on Wednesday, August 5, 2026, at 4:30 p.m. Eastern Time. Investors and interested parties can access the live webcast and replay on the company's investor relations website.

Pacific Biosciences of California, Inc. announced that Christopher M. Smith resigned from its Board of Directors, effective immediately on July 8, 2026. The company stated that it is not aware of any disagreement between Mr. Smith and the company regarding its operations, policies, or practices that led to his resignation.

Pacific Biosciences of California, Inc. announced that its stockholders approved an amendment to the 2020 Equity Incentive Plan, reserving an additional 16,000,000 shares of common stock for issuance. The Annual Meeting also saw the election of four Class III directors, the ratification of Ernst & Young LLP as the independent auditor for 2026, and the advisory approval of named executive officer compensation. Approximately 65% of the company's outstanding shares were represented at the meeting.

PacBio announced the global commercial availability of its SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for the Revio HiFi sequencing platform. This launch significantly reduces the per-genome list price to $345, with potential for sub-$300 at scale. The company also highlighted advancements in AI-powered DeepConsensus and expanded methylation detection, including a new 5hmC caller, which enhance data quality and biological insights. Beta testing across 20 sites demonstrated strong run performance, increased yield, and lower failure rates.

PacBio announced that its management will participate in a fireside chat at the Jefferies' Global Healthcare Conference on June 4, 2026, at 2:00 PM ET. The event will take place in New York, New York, and a live webcast will be available on the company's investor relations page. A replay of the webcast will also be accessible for at least 30 days following the conference.

PacBio announced the publication of a preprint from the HiFi Solves Sub-fertility Consortium in Asia Pacific, highlighting how HiFi whole genome sequencing can offer a more complete view of reproductive genetics in one workflow. The multicenter study, involving 96 individuals, identified clinically relevant genomic findings in approximately one in 10 couples, with likely diagnostic findings in 4.8% of individuals. This collaborative effort, supported by DNAstack’s federated analysis framework, aims to reduce fragmented testing and shorten the path to insight for subfertile couples, with plans for further expansion and evaluation of scalable workflows.

Pacific Biosciences reported a significant reduction in its net loss for Q1 2026, narrowing to $8.3 million from $426.1 million in Q1 2025, primarily due to the absence of a large amortization charge from the prior year. Total revenue remained flat at $37.2 million. The company completed an asset sale to Illumina for $50.0 million cash, resulting in a $45.8 million gain, and incurred $15.4 million in settlement charges related to a patent infringement lawsuit with Personal Genomics of Taiwan.

PacBio announced its first quarter 2026 financial results, reporting a significant reduction in GAAP net loss to $8.3 million, a substantial improvement from the $426.1 million loss in Q1 2025. Total revenue remained flat year-over-year at $37.2 million, with consumable revenue increasing to $21.8 million while instrument revenue declined to $9.7 million. The company also completed the sale of short-read sequencing assets for $48.1 million and provided full-year 2026 revenue guidance of $165 million to $175 million, alongside progress in its SPRQ-Nx beta program and new collaborations.

PacBio announced that Lucid Genomics GmbH has joined its PacBio Compatible partner program. This collaboration integrates Lucid Genomics' bioinformatics software for tertiary analysis with PacBio's HiFi long-read sequencing technology, aiming to streamline the interpretation and reporting of genomic variants. The partnership is expected to help scientists and clinical researchers more efficiently derive actionable insights from sequencing data, enhancing the value of PacBio's technology across the workflow.